|
1
|
Egashira A, Morita M, Kumagai R, Taguchi
KI, Ueda M, Yamaguchi S, Yamamoto M, Minami K, Ikeda Y and Toh Y:
Neuroendocrine carcinoma of the esophagus: Clinicopathological and
immunohistochemical features of 14 cases. PLoS One.
12:e01735012017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dasari A, Mehta K, Byers LA, Sorbye H and
Yao JC: Comparative study of lung and extrapulmonary poorly
differentiated neuroendocrine carcinomas: A SEER database analysis
of 162 983 cases. Cancer. 124:807–815. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
WHO Classification of Tumours Editorial
Board, . WHO classification of tumours: Digestive system tumours.
5th edition. International Agency for Research on Cancer; Lyon:
2019
|
|
4
|
Wong AT, Shao M, Rineer J, Osborn V,
Schwartz D and Schreiber D: Treatment and survival outcomes of
small cell carcinoma of the esophagus: An analysis of the national
cancer data base. Dis Esophagus. 30:1–5. 2017.
|
|
5
|
Deng HY, Li G, Luo J, Li XR, Alai G and
Lin YD: The role of surgery in treating resectable limited disease
of esophageal neuroendocrine carcinoma. World J Surg. 42:2428–2436.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cai W, Ge W, Yuan Y, Ding K, Tan Y, Wu D
and Hu H: A 10-year population-based study of the differences
between NECs and carcinomas of the esophagus in terms of
clinicopathology and survival. J Cancer. 10:1520–1527. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines®), . Poorly differentiated neuroendocrine
carcinoma/large or small cell. Neuroendocrine and Adrenal Tumors.
NCCN. version 1. 2019
|
|
8
|
Ito T, Masui T, Komoto I, Doi R, Osamura
RY, Sakurai A, Ikeda M, Takano K, Igarashi H, Shimatsu A, et al:
JNETS clinical practice guidelines for gastroenteropancreatic
neuroendocrine neoplasms: diagnosis, treatment, and follow-up: A
synopsis. J Gastroenterol. 56:1033–1044. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niwa Y, Yamada S, Sonohara F, Kurimoto K,
Hayashi M, Tashiro M, Iwata N, Kanda M, Tanaka C, Kobayashi D, et
al: Identification of a serum-based miRNA signature for response of
esophageal squamous cell carcinoma to neoadjuvant chemotherapy. J
Transl Med. 17:12019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoshino I, Ishige F, Iwatate Y, Gunji H,
Kuwayama N, Nabeya Y, Yokota H, Takeshita N, Iida K, Nagase H and
Matsubara H: Cell-free microRNA-1246 in different body fluids as a
diagnostic biomarker for esophageal squamous cell carcinoma. PLoS
One. 16:e02480162021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang H, Su H, Hu N, Wang C, Wang L, Giffen
C, Goldstein AM, Lee MP and Taylor PR: Integrated analysis of
genome-wide miRNAs and targeted gene expression in esophageal
squamous cell carcinoma (ESCC) and relation to prognosis. BMC
Cancer. 20:3882020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xi Y, Nakajima G, Gavin E, Morris CG, Kudo
K, Hayashi K and Ju J: Systematic analysis of microRNA expression
of RNA extracted from fresh frozen and formalin-fixed
paraffin-embedded samples. RNA. 13:1668–1674. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Osawa S, Shimada Y, Sekine S, Okumura T,
Nagata T, Fukuoka J and Tsukada K: MicroRNA profiling of gastric
cancer patients from formalin-fixed paraffin-embedded samples.
Oncol Lett. 2:613–619. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lloyd RV, Osamura RY, Klöppel G and Rosai
J: WHO classification of tumours of endocrine organs. Lloyd RV: WHO
classification of tumours. 4th edition. 10. Lyon: International
Agency for Research on Cancer; 2017
|
|
16
|
Sobin LH, Gospodarowicz M and Wittekind C:
TNM Classification of Malignant Tumours. 7th edition. UICC
International Union Against Cancer Hoboken, NJ: Wiley-Blackwell;
2010, PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Breiman L: Random forests. Mach Learn.
45:5–32. 2001. View Article : Google Scholar
|
|
19
|
Altmann A, Toloşi L, Sander O and Lengauer
T: Permutation importance: A corrected feature importance measure.
Bioinformatics. 26:1340–1347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jatoi A and Miller RC: Should we recommend
surgery to patients with limited small cell carcinoma of the
esophagus? J Thorac Oncol. 3:1373–1376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu L, Li Y, Liu X, Sun H, Zhang R, Zhang
J, Zheng Y, Wang Z, Liu S and Chen X: Treatment strategies and
prognostic factors of limited-stage primary small cell carcinoma of
the esophagus. J Thorac Oncol. 12:1834–1844. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang G, Wu B, Wang X and Li J: A
competing-risks nomogram and recursive partitioning analysis for
cause-specific mortality in patients with esophageal neuroendocrine
carcinoma. Dis Esophagus. 32:doy1292019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zou B, Li T, Zhou Q, Ma D, Chen Y, Huang
M, Peng F, Xu Y, Zhu J, Ding Z, et al: Adjuvant therapeutic
modalities in primary small cell carcinoma of esophagus patients: A
retrospective cohort study of multicenter clinical outcomes.
Medicine (Baltimore). 95:e35072016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Watanabe M, Otake R, Kozuki R, Toihata T,
Takahashi K, Okamura A and Imamura Y: Recent progress in
multidisciplinary treatment for patients with esophageal cancer.
Surg Today. 50:12–20. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Honma Y, Nagashima K, Hirano H, Shoji H,
Iwasa S, Takashima A, Okita N, Kato K, Boku N, Murakami N, et al:
Clinical outcomes of locally advanced esophageal neuroendocrine
carcinoma treated with chemoradiotherapy. Cancer Med. 9:595–604.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sorbye H, Welin S, Langer SW, Vestermark
LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K,
et al: Predictive and prognostic factors for treatment and survival
in 305 patients with advanced gastrointestinal neuroendocrine
carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol. 24:152–160.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abraham KJ, Zhang X, Vidal R, Paré GC,
Feilotter HE and Tron VA: Roles for miR-375 in neuroendocrine
differentiation and tumor suppression via notch pathway suppression
in merkel cell carcinoma. Am J Pathol. 186:1025–1035. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
García-Martínez A, López-Muñoz B, Fajardo
C, Cámara R, Lamas C, Silva-Ortega S, Aranda I and Picó A:
Increased E2F1 mRNA and miR-17-5p expression is correlated to
invasiveness and proliferation of pituitary neuroendocrine tumours.
Diagnostics (Basel). 10:2272020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Calsina B, Castro-Vega LJ, Torres-Pérez R,
Inglada-Pérez L, Currás-Freixes M, Roldán-Romero JM, Mancikova V,
Letón R, Remacha L, Santos M, et al: Integrative multi-omics
analysis identifies a prognostic miRNA signature and a targetable
miR-21-3p/TSC2/mTOR axis in metastatic
pheochromocytoma/paraganglioma. Theranostics. 9:4946–4958. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J,
Zhou K, Liu X, Ren X, Wang F, et al: Cancer-derived exosomal
miR-25-3p promotes pre-metastatic niche formation by inducing
vascular permeability and angiogenesis. Nat Commun. 9:53952018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Trivellin G, Butz H, Delhove J, Igreja S,
Chahal HS, Zivkovic V, McKay T, Patócs A, Grossman AB and Korbonits
M: MicroRNA miR-107 is overexpressed in pituitary adenomas and
inhibits the expression of aryl hydrocarbon receptor-interacting
protein in vitro. Am J Physiol Endocrinol Metab. 303:E708–E719.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Di W, Amdanee N, Zhang W and Zhou Y:
Long-term exercise-secreted extracellular vesicles promote browning
of white adipocytes by suppressing miR-191a-5p. Life Sci.
263:1184642020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peng W, Li J, Chen R, Gu Q, Yang P, Qian
W, Ji D, Wang Q, Zhang Z, Tang J and Sun Y: Upregulated METTL3
promotes metastasis of colorectal cancer via miR-1246/SPRED2/MAPK
signaling pathway. Exp Clin Cancer Res. 38:3932019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sugita BM, Pereira SR, de Almeida RC, Gill
M, Mahajan A, Duttargi A, Kirolikar S, Fadda P, de Lima RS, Urban
CA, et al: Integrated copy number and miRNA expression analysis in
triple negative breast cancer of Latin American patients.
Oncotarget. 10:6184–6203. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park S, Kim J, Cho Y, Ahn S, Kim G, Hwang
D, Chang Y, Ha S, Choi Y, Lee MH, et al: Promotion of tumorigenesis
by miR-1260b-targeting CASP8: Potential diagnostic and prognostic
marker for breast cancer. Cancer Sci. 113:2097–2108. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang P, Chen W, Zhang Y, Zhong Q, Li Z and
Wang Y: MicroRNA-1246 suppresses the metastasis of breast cancer
cells by targeting the DYRK1A/PGRN axis to prevent the
epithelial-mesenchymal transition. Mol Biol Rep. 49:2711–2721.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rammohan M, Harris E, Bhansali RS, Zhao E,
Li LS and Crispino JD: The chromosome 21 kinase DYRK1A: Emerging
roles in cancer biology and potential as a therapeutic target.
Oncogene. 41:2003–2011. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li G, Dong T, Yang D, Gao A, Luo J, Yang H
and Wang L: Progranulin promotes lymphangiogenesis through VEGF-C
and is an independent risk factor in human esophageal cancers. Hum
Pathol. 75:116–124. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu N, Jia D, Ibrahim AH, Bachurski CJ,
Gronostajski RM and MacPherson D: NFIB overexpression cooperates
with Rb/p53 deletion to promote small cell lung cancer. Oncotarget.
7:57514–57524. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Andreasen S, Persson M, Kiss K, Homøe P,
Heegaard S and Stenman G: Genomic profiling of a combined large
cell neuroendocrine carcinoma of the submandibular gland. Oncol
Rep. 35:2177–2182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Q, Cao LY, Cheng SJ, Zhang AM, Jin
XS and Li Y: p53-induced microRNA-1246 inhibits the cell growth of
human hepatocellular carcinoma cells by targeting NFIB. Oncol Rep.
33:1335–1341. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Tanaka Y, Tabatabai ZL and Dahiya R: Correction: Genistein
downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via
demethylation and histone modification in prostate cancer cells. Br
J Cancer. 119:3882018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim JT, Li J, Jang ER, Gulhati P, Rychahou
PG, Napier DL, Wang C, Weiss HL, Lee EY, Anthony L, et al:
Deregulation of Wnt/β-catenin signaling through genetic or
epigenetic alterations in human neuroendocrine tumors.
Carcinogenesis. 34:953–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim H, An S, Lee K, Ahn S, Park DY, Kim
JH, Kang DW, Kim MJ, Chang MS, Jung ES, et al: Pancreatic
high-grade neuroendocrine neoplasms in the Korean population: A
multicenter study. Cancer Res Treat. 52:263–276. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou X, You M, Wang F, Wang Z, Gao X, Jing
C, Liu J, Guo M, Li J, Luo A, et al: Multifunctional
graphdiyne-cerium oxide nanozymes facilitate MicroRNA delivery and
attenuate tumor hypoxia for highly efficient radiotherapy of
esophageal cancer. Adv Mater. 33:e21005562021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Okumura T, Shimada Y, Omura T, Hirano K,
Nagata T and Tsukada K: MicroRNA profiles to predict postoperative
prognosis in patients with small cell carcinoma of the esophagus.
Anticancer Res. 35:719–727. 2015.PubMed/NCBI
|
|
47
|
Latchana N, DiVincenzo MJ, Regan K, Abrams
Z, Zhang X, Jacob NK, Gru AA, Fadda P, Markowitz J, Howard JH and
Carson WE III: Alterations in patient plasma microRNA expression
profiles following resection of metastatic melanoma. J Surg Oncol.
118:501–509. 2018.PubMed/NCBI
|
|
48
|
Yao Y, Ding Y, Bai Y, Zhou Q, Lee H, Li X
and Teng L: Identification of serum circulating MicroRNAs as novel
diagnostic biomarkers of gastric cancer. Front Genet.
11:5915152021. View Article : Google Scholar : PubMed/NCBI
|
